Skyrizi 180 mg/1.2mL

Skyrizi 180 mg/1.2mL is a subcutaneous injection used for managing moderate to severe plaque psoriasis. This medication, containing risankizumab-rzaa, is designed to help reduce inflammation and improve skin condition.

Skyrizi 180 mg/1.2mL is primarily used for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy or phototherapy. This medication works by targeting specific proteins in the body to reduce inflammation and slow down the overproduction of skin cells. People often ask, 'What is Skyrizi used for?' and the answer is that it is intended for those who have not responded well to other treatments or who have severe forms of psoriasis.

Common effects of Skyrizi 180 mg/1.2mL may include reactions at the injection site, such as redness, itching, or swelling. Some users might experience upper respiratory infections, fatigue, or headache. These effects are generally mild and temporary, but it's important to monitor any persistent or severe symptoms.

Skyrizi 180 mg/1.2mL should be handled with care, ensuring proper storage and administration as directed. It is important to inform healthcare providers about any allergies or medical conditions before use. This medication should not be used by individuals who are allergic to risankizumab-rzaa or any of its components.

Skyrizi 180 mg/1.2mL may interact with other medications, including those that affect the immune system. It is advisable to consult with a healthcare provider before combining this medication with other treatments. Alcohol and certain supplements might also interact with Skyrizi, so it's important to discuss all current medications with a healthcare professional.